With only nine trading days left this year, it appears that biopharma will finish 2016 underwater and close the doors on what will go down as one of the sector's worst performing 12 months for several years. Read More
Another day, another research consortium – at least that's the way it sometimes feels early stage drug development is playing out. From Alzheimer's disease (AD) to Zika virus, the upswing in biopharma consortia is unmistakable. Although tangible results are sometimes hard to quantify, the consortium model appears to be gaining momentum because it delivers on its promise: enabling allies as well as erstwhile competitors to collaborate in an environment where the accrual and sharing of information advances a greater good. Read More
